Tertomotide is under clinical development by GemVax & KAEL and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Tertomotide’s likelihood of approval (LoA) and phase transition for Metastatic Colorectal Cancer took place on 28 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tertomotide Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Tertomotide overview

Tertomotide hydrochloride (Riavax) is a peptide vaccine. It is formulated as lyophilized powder for solution for intradermal route of administration. Riavax is indicated for the treatment of locally advanced or metastatic pancreatic cancer patients whose serum eotaxin level is higher than 81.02pg/mL. Tertomotide hydrochloride is indicated for emergency use in the treatment of coronavirus disease 2019 (COVID-19) associated cytokine release syndrome. The vaccine candidate is under development for the treatment of Alzheimer's disease, pancreatic ductal adenocarcinoma, benign prostatic hyperplasia and prostate cancer, non small cell lung cancer, hepatitis B and Coronavirus disease (COVID-19). The vaccine candidate is administered through intradermal and subcutaneous route. The vaccine candidate targets telomerase. It was also under development for the treatment of colorectal cancer, chronic lymphocytic leukemia (CLL), non-small cell lung cancer, allergic rhinitis, multiple sclerosis, rheumatoid arthritis, sepsis, ischemia reperfusion injury, periodontitis, cancer cachexia, kidney disease, hepatocellular carcinoma, melanoma, metastatic adenocarcinoma of pancreas (global) and asthma.

GemVax & KAEL overview

GemVax & KAEL, is a pharmaceutical company. It develops and manufactures anti-cancer immunotherapeutic and peptide drugs to treat cancer. The company’s lead product candidate RIAVAX (GV1001), an immunotherapeutic peptide is used for the treatment of advanced or metastatic pancreatic cancer. GemVax & KAEL is also investigating GV1001 drug, against prostate cancer, benign prostate enlargement, Alzheimer’s disease and non-small cell lung carcinoma (NSCLC). The company is also involved in manufacture of pollution control equipment used in semiconductor manufacturing processes. The company offers coating resins and filters for producing semi-conductors and panel displays through its filter division. The Company distributes its products within domestic market and to overseas markets. GemVax & KAEL is headquartered in Dajeon, Korea.

Quick View Tertomotide LOA Data

Report Segments
  • Innovator (NME)
Drug Name
  • Tertomotide
Administration Pathway
  • Intradermal
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Genito Urinary System And Sex Hormones
  • Immunology
  • Infectious Disease
  • Male Health
  • Mouth and Dental Disorders
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.